Who are Lisata Therapeutics, Inc.'s investors?

Lisata Therapeutics, Inc.'s investors include Kyoto University Innovation Capital.

How much funding has Lisata Therapeutics, Inc. raised?

Lisata Therapeutics, Inc. has disclosed $435.1M raised across 8 rounds.

Where is Lisata Therapeutics, Inc. headquartered?

Lisata Therapeutics, Inc. is headquartered in Basking Ridge, US.

Lisata Therapeutics, Inc.

NASDAQ: LSTA

Basking Ridge, US · Founded 2006 · 1 known investors

Find your way into Lisata Therapeutics, Inc.

Paths you didn't know you had: your email and LinkedIn already hold routes to the Lisata Therapeutics, Inc. team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Lisata develops drug delivery platform technology and therapies for solid tumors, enabling targeted anti-cancer drug delivery and immune system activation against cancer.

Biotech Medical Devices

Founders & leadership

Joseph TalamoExecutive

Robert A. PretiDirector2016–2017Executive Officer, Director at Caladrius Biosciences

Andrew L. Pecora ExecutiveDirector at Caladrius Biosciences

Stephen W. PotterExecutive Vice President2013–2015Executive Officer at Caladrius Biosciences

Robert Dickey IVExecutive

Catherine VaczyCo-founder, General Counsel and Corporate Secretary2005–2015Executive Officer at Caladrius Biosciences

Douglas Losordo ExecutiveExecutive Officer at Cadrenal Therapeutics

David J. Mazzo President and Chief Executive Officer, Member of the Board of Directors at Lisata TherapeuticsDavid J. Mazzo holds a Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst, and has spent over four decades in pharmaceutical executive roles at companies including Schering-Plough Research Institute, Hoechst Marion Roussel, Rhone-Poulenc Rorer, Chugai Pharma USA, Æterna Zentaris, and Regado Biosciences. He is President and Chief Executive Officer of Lisata Therapeutics, a NASDAQ-listed company developing drug delivery technology for solid tumors.

Kristen K. Buck Chief Medical Officer and EVP, Head of R&D at Lisata Therapeutics (formerly Caladrius)Board-certified internal medicine physician with over 20 years of drug development and clinical experience, including roles as medical officer at the FDA, chief medical officer at multiple biotechnology and medical device companies, and leadership of clinical development and regulatory affairs functions across oncology, cardiovascular, and other therapeutic areas.

James Nisco Senior Vice President, Finance and Treasury and Chief Accounting OfficerJames Nisco is Senior Vice President of Finance and Treasury and Chief Accounting Officer at Lisata Therapeutics, a company developing drug delivery platform technology for targeted cancer therapies. He has held finance and accounting roles across companies of various sizes, with expertise in SEC reporting, financial planning, and treasury operations.

TARIQ IMAMSenior Vice President, Business Development & Licensing, Operations and General CounselExecutive Officer at Caladrius Biosciences

GREGORY BROWNNamed on SEC filing

Investors · 1

Kyoto University Innovation Capitallisted by Kyoto University Innovation CapitalKyoto

How we know: Kyoto University Innovation Capital's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$435.1M disclosed across 8 rounds · 2014–2026

▶$351.9MraisedOct 2026 · 20 investors · Biotechnology

Rule 506(b)